Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Big pharma leads the way in stock market resurgence
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Delays look like the best-case scenario for teplizumab
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Drug rejections hold steady in 2020
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
New Nuplazid use in limbo after US knockback
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.
Biogen’s Sage advice amounts to $1.5bn
Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
